Tarsus Pharmaceuticals Inc (TARS)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex ... Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Show more
Ask ADVFN Intelligence (AI)
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two...
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.56 | 1.08569212873 | 51.58 | 54.44 | 49.35 | 423575 | 51.0898232 | CS |
| 4 | -0.0999 | -0.191233137889 | 52.2399 | 54.44 | 43.2501 | 590639 | 48.21728124 | CS |
| 12 | 18.91 | 56.9064098706 | 33.23 | 54.44 | 31.36 | 706051 | 42.51324151 | CS |
| 26 | 18.48 | 54.9019607843 | 33.66 | 54.44 | 20.0818 | 744119 | 34.00460629 | CS |
| 52 | 34.14 | 189.666666667 | 18 | 54.44 | 17.45 | 711679 | 32.43233301 | CS |
| 156 | 28.44 | 120 | 23.7 | 54.44 | 10.8001 | 376629 | 26.50309511 | CS |
| 260 | 33.84 | 184.918032787 | 18.3 | 63.69 | 10.8001 | 287142 | 26.84230098 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
